Psychiatyr Clin Neurosci 58, 359-363, (2004). Satoh, F., Miyatake, R., Furukawa, A., & Suwaki, H View abstract in PubMed Post navigationPreviousPrevious post:Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumour and self-reliant cells and inhibit tumor growth in vitro and in vivo.NextNext post:Sigma-1 receptor upregulation after chronic methamphetamine self-administration in rats: A study with yoked controls.Related PostsAnavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett SyndromeJuly 29, 2019Anavex Life Sciences to Present at the 30th Annual ROTH ConferenceMarch 9, 2018Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett SyndromeJuly 31, 2019
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett SyndromeJuly 29, 2019
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)March 7, 2018
